Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 10184Neoplasms 7810Carcinoma, Non-Small-Cell Lung 5760Prostatic Neoplasms 5024Colorectal Neoplasms 4606Lung Neoplasms 3725Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3083Multiple Myeloma 3082Pancreatic Neoplasms 2845Melanoma 2653Ovarian Neoplasms 2573Lymphoma 2571Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Recurrence 2230Head and Neck Neoplasms 2103Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia 2013Brain Neoplasms 1905Glioblastoma 1797Colonic Neoplasms 1791Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1720Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1652Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

Trastuzumab 2liposomal doxorubicin 1eribulin 1Metformin 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × HER-2 Positive Breast Cancer × Clear all
NCT02488564 2025-02-03

met-HEReMYTA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed
49 enrolled
Breast

HER-2 Positive Breast Cancer

NCT05871918 2023-05-23

A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Unknown
832 enrolled
Breast

HER-2 Positive Breast Cancer

NCT01388647 2015-08-28

Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

Vector Oncology

Phase 1/2 Terminated
12 enrolled 12 charts
Breast

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡